Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

167
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
167
Coagulation01:09

Coagulation

9.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.1K
Coagulation01:06

Coagulation

914
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
914
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Biomarker-Associated Therapy in Metastatic Carcinoma of Unknown Primary: Prevalence, Impact, and Outcomes.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways.

bioRxiv : the preprint server for biology·2026
Same author

Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis.

Clinical lung cancer·2025
Same author

Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database.

Cancer medicine·2025
Same author

Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.

Therapeutic advances in vaccines and immunotherapy·2024
Same author

Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report.

Cureus·2024

Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

Coagulation and anticoagulation in COVID-19.

Tarik Hadid1, Zyad Kafri1, Ayad Al-Katib2

  • 1Department of Internal Medicine, Wayne State University, School of Medicine, Detroit, MI, USA; Ascension Michigan, Detroit, MI, USA.

Blood Reviews
|October 17, 2020
PubMed
Summary

COVID-19-induced coagulopathy (CIC) presents uniquely, differing from sepsis. Researchers propose a new scoring system to guide anticoagulation therapy for COVID-19 patients, addressing a critical treatment gap.

Keywords:
AnticoagulationCOVID-19COVID-19 induced coagulopathyCoagulationCoagulopathyThrombosis

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Related Experiment Videos

Last Updated: Dec 5, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Area of Science:

  • * Internal Medicine
  • * Hematology
  • * Infectious Diseases

Background:

  • * COVID-19 pandemic presents unique coagulopathy (CIC), distinct from sepsis-induced coagulopathy.
  • * CIC involves elevated D-dimer and fibrin split products, with minimal changes in aPTT/PT.
  • * Severe cytokine storm in COVID-19 leads to widespread thrombosis and organ failure.

Purpose of the Study:

  • * To propose a scoring system for COVID-19-induced coagulopathy (CIC Scoring).
  • * To stratify patients based on risk categories for targeted anticoagulation therapy.
  • * To address the lack of established practice guidelines for CIC management.

Main Methods:

  • * Development of a novel scoring system (CIC Scoring) based on clinical and laboratory findings.
  • * Risk stratification framework for guiding anticoagulation decisions.
  • * Literature review and expert consensus on CIC pathophysiology and treatment.

Main Results:

  • * Proposed CIC Scoring system to quantify coagulopathy severity.
  • * Risk categories established for tailored anticoagulation strategies.
  • * Highlighted the critical role of anticoagulation in managing COVID-19 complications.

Conclusions:

  • * The proposed CIC Scoring system offers a framework for managing COVID-19-induced coagulopathy.
  • * Risk stratification is essential for optimizing anticoagulation therapy in these patients.
  • * Further research and data are needed to refine guidelines in this evolving field.